Mebendazole Loaded Nanoparticles for Lung Cancer Therapy

Abstract

Lung cancer is the leading cause of cancer mortality. Lung cancers are classified into two types based on their microscopic appearance: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Many individuals are first diagnosed at stage III or IV, when their prognosis is bleak. Non-small cell lung cancer is a lethal and incurable illness that can be treated with surgery, chemotherapy, radiation therapy, targeted therapy, or a combination of therapies. Targeted treatment focuses on particular abnormalities seen in cancer cells, such as the Epidermal growth factor receptor (EGFR) mutation. The T 790M mutation in the EGFR’s tyrosine kinase domain causes acquired resistance to first-generation EGFR TKIs, mebendazole. As a result, combining diverse targeted therapeutic drugs not only improves treatment outcomes but can also be a more effective preventer of acquired resistance improvement. Loaded drug Nanoparticles ZSM-5 and SBA-16 were utilized as targeted treatment, and their stability and loading % were determined using multiple methods, including infrared, X-Ray Diffraction, TGA, and HPLC. The therapy was used in in-vitro cell culture investigations such as the MMT assay, colony assay, and migration assay. The results showed that the loaded drug nanoparticles had a lower IC50 than the free drug mebendazole we utilized, indicating that the nanoparticles improved therapy and reduced medication dosage.